Lipid Nanoparticles Formulated with a Novel Cholesterol-Tailed Ionizable Lipid Markedly Increase mRNA Delivery Both in vitro and in vivo
International Journal of Nanomedicine · 2025-07 · Volume 20 · 9389-9405
DOI: 10.2147/ijn.s527822 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025-07. Verfasst von Ju Hyeong Jeon und 10 weiteren Autor:innen. Beteiligte Einrichtung: ARV Technologies, Inc, North Bethesda, MD, 20852, USA. Hauptthemen laut MEDLINE: Nanoparticles, RNA, Messenger, Cholesterol, Lipids. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Lipid nanoparticles (LNPs) have emerged as the most successful, effective, and safe method for RNA delivery, and have shown tremendous potential for the treatment of various diseases, such as messenger RNA (mRNA) vaccines, gene editing, and RNA interface (RNAi) therapies. The development of novel ionizable lipids holds great promise in improving the efficacy and safety of LNPs.
Methods
We synthesized a novel ionizable lipid, ARV-T1, with a cholesterol moiety incorporated in its tail. We characterized the physicochemical properties of LNPs formulated with ARV-T1, calculated the pKa of ARV-T1, and conducted in vitro and in vivo mRNA delivery studies.
Results
ARV-T1 has a pKa value of 6.73, and compared to SM-102, the ionizable lipid used in the Moderna SARS-CoV2 vaccine, the LNPs formulated with ARV-T1 showed smaller particle sizes, lower polydispersity indices, and higher absolute zeta potential values. More importantly, the LNPs formulated with ARV-T1 showed significantly increased mRNA delivery both in vitro and in vivo, markedly increased protein expression, and demonstrated more than 10-fold higher potency in inducing SARS-CoV-2 spike protein binding antibodies and SARS-CoV-2 virus neutralizing antibodies in mice compared to the LNPs formulated with SM-102. Furthermore, the unique ester linkage of ARV-T1 enables rapid and complete metabolism in vivo, thereby improving its biocompatibility and safety profile.
Conclusion
These findings suggest that the novel ionizable lipid ARV-T1 holds great promise for the development of mRNA vaccines and other mRNA-based therapeutics and may pave the way for the development of safer and more effective mRNA delivery systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ARV Technologies, Inc, North Bethesda, MD, 20852, USA.
- Department of Otorhinolaryngology-Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, People's Republic of China.
- Department of Biology and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
ORCID-Profile: Stephanie Mou, Ramesh Marasini, Xinle Cui
Zitieren
APA
Jeon, J. H., Zhu, H., Qin, J., Wang, L., Mou, S., Langston, L. K., Marasini, R., Chen, J., Xu, R., Li, S., & Cui, X. (2025). Lipid Nanoparticles Formulated with a Novel Cholesterol-Tailed Ionizable Lipid Markedly Increase mRNA Delivery Both in vitro and in vivo. International Journal of Nanomedicine, Volume 20, 9389-9405. https://doi.org/10.2147/ijn.s527822
Vancouver
Jeon JH, Zhu H, Qin J, Wang L, Mou S, Langston LK, et al. Lipid Nanoparticles Formulated with a Novel Cholesterol-Tailed Ionizable Lipid Markedly Increase mRNA Delivery Both in vitro and in vivo. International Journal of Nanomedicine. 2025;Volume 20:9389-9405. doi:10.2147/ijn.s527822
BibTeX
@article{Jeon2025,
author = {Jeon, Ju Hyeong and Zhu, Huabin and Qin, Jane and Wang, Luyao and Mou, Stephanie and Langston, Laura Katherine and Marasini, Ramesh and Chen, Jianzhu and Xu, Renhuan and Li, Shuna and Cui, Xinle},
title = {Lipid Nanoparticles Formulated with a Novel Cholesterol-Tailed Ionizable Lipid Markedly Increase mRNA Delivery Both in vitro and in vivo},
journal = {International Journal of Nanomedicine},
year = {2025},
volume = {Volume 20},
pages = {9389--9405},
doi = {10.2147/ijn.s527822}
}
EUVIMED